Current treatment of multiple sclerosis;A sclerosis multiplex kezelése napjainkban

Lege Artis Medicinae

Volumn 21, Issue 2, 2011, Pages 97-103

  Csépány, Tünde ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Cladribine; Dimethyl fumarate; Fingolimod; Glatiramer acetate; Interferon beta; Laquinimod; Mitoxantron; Multiple sclerosis; Natalizumab

Indexed keywords

BETA INTERFERON; CLADRIBINE; DRUG DERIVATIVE; FINGOLIMOD; FUMARIC ACID DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; LAQUINIMOD; MONOCLONAL ANTIBODY; NATALIZUMAB; PEPTIDE; PROPANEDIOL DERIVATIVE; QUINOLONE DERIVATIVE; SPHINGOSINE;

DRUG ADMINISTRATION; HUMAN; IMMUNOLOGY; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL; CLADRIBINE; DRUG ADMINISTRATION SCHEDULE; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PROPYLENE GLYCOLS; QUINOLONES; SPHINGOSINE; TREATMENT OUTCOME;

EID: 79952920492     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Bencsik K, Rajda C, Füvesi J, Klivényi P, Járdánházy T, Török M, et al. The prevalance of multiple sclerosis, distribution of clinical forms of the disease and functional status of patients in Csongrad county, Hungary. Eur Neurol 2001;46:206-9. (Pubitemid 33135795)
2. Lovas G, Szilágyi N, Majtényi K, Palkovits M, Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000;123:308-17. (Pubitemid 30055154)
3. Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 2007;17:38-44.
4. Lassmann H. Multiple sclerosis: is there neurodegeneration independent from inflammation? J Neurol Sci 2007; 259:3-6. (Pubitemid 47031195)
5. Komoly S. Experimental demyelination caused by primary oligodendrocyte dystrophy. Regional distribution of the lesions in the nervous system of mice brain. Ideggyogy Sz 2005;58:40-3.
6. Benesová Y, Vašku A, Novotná H, Litzman J, Stourac P, Beránek M, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler 2009;15:316-22.
7. Rajda C, Bencsik K, Seres E, Jonasdottir A, Foltynie T, Sawcer S, et al. A genome-wide screen for association in Hungarian multiple sclerosis. J Neuroimmunol 2003;143:84-7. (Pubitemid 37324290)
8. International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, et al. Risk alleles for. multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357:851-62.
9. De Jager PL. Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future. Ther Adv Neurol Disord 2009;2:369-77.
10. Illes Z. Sclerosis multiplex és autoimmunitás az ezredfordulón. Pécs: PTE Neurológiai Klinika; 2003.
11. Csépány T, Illés Zs. Klinikai neuroimmunoló gia. Kaposvár: Matyus-BENTEN kiadó; 2005.
12. McDonald WI, Compston A, Edan G, Goodkin D, Härtung HP, Lublin FD, et al. Recommended Diagnostic Criteria for MS. Ann Neurol 2001;50:121-7.
13. Polman CH, Reingold SC, Edan G, Filippi M, Härtung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol 2005;58:840-46. (Pubitemid 41746873)
14. Bar-Zohar D, Agosta E Goldstaub D, Filippi M. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives. Mult Scler 2008;14:719-27.
15. Weiner HL. The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease? Ann Neurol 2009;65:239-48.
16. Vécsei L, Komoly S (szerk.). Sclerosis multiplex. Szekszárd: Therapia kiadó; 2003.
17. Csépány T, Mezei Z, Csiba L. Immunmoduláns kezeléssel szerzett tapasztalatok és ajánlások sclerosis multiplexben. Orvostudományi Értesíto 2009;82:74-8.
18. Rammohan KW, Shoemaker J. Emerging multiple sclerosis oral therapies. Neurology 2010;74;S47-S53.
19. Syc S, Schiess N. Emerging Therapies for Multiple Sclerosis Update on Current Clinical Trials. Int J MS Care 2010;12: 17-22.
20. Freedman M. Time is brain' also in multiple sclerosis. Mult Scler 2009;15:1133-4.
21. Jacobs LD, Beck RW Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, etal. Intramuscular interferon beta-1 a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
22. Kappos L, Polman CH, Freedman MS, Edan G, Härtung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9. (Pubitemid 44563835)
23. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo controlled trial. Lancet 2009;374:1503-11.
24. Gilmore CP, Cottrell DA, Scolding NJ, Wingerchuk DM, Weinshenker BG, Boggild M. A window of opportunity for no treatment in early multiple sclerosis? Multiple Sclerosis 2010;16:756-9.
25. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-25. (Pubitemid 36026580)
26. Sfüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 2007;64:169-76.
27. Rajda C, Bencsik K, Vécsei L. Magyarországi Sclerosis Multiplex Centrumok Orvosi Tanácsadó Testület tagjai. A natalizumab alkalmazása sclerosis multiplexben. Ideggyogy Sz 2008;61:204-8.
28. Bielekova B, Becker BL. Monoclonal antibodies in MS: Mechanisms of action. Neurology 2010;74;S31-S40.
29. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9:425-37.
30. Kappos L, Radue E-M, O'Connor P, Polman C, Hohlfeld R, Calabres! P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362387-401.
31. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
32. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, et al. CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26.
33. Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010;16:342-50.
34. Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, et al. Investigators of the 16-Year Long-Term Follow-Up Study. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology 2010;74:1877-85.
35. De Jager PL. Review: Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges, for the future. Therapeutic Advances in Neurological Disorders 2009;2;369-77.
36. Pascual AM, Téllez N, Boscá I, Mallada J, Belenguer A, Abellán I, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler 2009;15:1303-10.
37. Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:1476-81. (Pubitemid 39264069)
38. Johnson KP. Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Ther Clin Risk Manag 2010;6:153-72.
39. Simó M. Therapy of multiple sclerosis. Neuropsychopharmacol Hung 2009; 1123-6.